Arylalkyl ureas as cb1 antagonists

Details Arylalkyl ureas as cb1 antagonists Arylalkyl ureas as cb1 antagonists

C - Chemistry, Metallurgy

07

C

C07C 273/00 (2006.01) C07C 275/00 (2006.01)

Patent

CA 2579227

CB1 antagonists are provided. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 receptor modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.

La présente invention concerne des antagonistes CB1. Ces composés peuvent être utilisés pour moduler l'activité CB1 in vivo ou in vitro et, conviennent particulièrement pour le traitement d'états sensibles à la modulation du récepteur CB1 chez l'homme, l'animal domestique et le bétail, notamment les troubles de l'appétit, l'obésité et les troubles toxicomanogènes. Cette invention concerne aussi des compositions et des procédés d'utilisation de celles-ci permettant de traiter ces troubles, tels que des procédés d'utilisation de ces ligands destinés à des études de localisation de récepteur et à divers dosages in vitro.

Affiliated with

Also associated with

Rating

Arylalkyl ureas as cb1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arylalkyl ureas as cb1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylalkyl ureas as cb1 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1927402